Angiogenesis inhibitor

This page covers all Angiogenesis inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Endothelial cells; inhibits multiple angiogenic pathways, Endothelial cells (multiple pathways including integrin and VEGF-related mechanisms), VEGF signaling pathway; endothelial cells.

Targets

Endothelial cells; inhibits multiple angiogenic pathways · Endothelial cells (multiple pathways including integrin and VEGF-related mechanisms) · VEGF signaling pathway; endothelial cells · Endothelial cells; inhibits VEGF-mediated angiogenesis · VEGFR2 · VEGF-A

Marketed (2)

• endostar+chemoradiotherapy · Second Affiliated Hospital of Xi'an Jiaotong University · Oncology
  Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors, used in combination with chemotherapy and radiotherapy to enhance anti-tumor effects.
• recombinant human endostatin · Peking University Cancer Hospital & Institute · Oncology
  Recombinant human endostatin inhibits angiogenesis by blocking new blood vessel formation in tumors.

Phase 3 pipeline (6)

• Rh-endostatin · Guangzhou Institute of Respiratory Disease · Oncology
  Rh-endostatin inhibits angiogenesis by blocking new blood vessel formation, thereby starving tumors of their blood supply.
• ENDOSTAR，cisplatin · Jiangsu Simcere Pharmaceutical Co., Ltd. · Oncology
  Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation, used in combination with cisplatin chemotherapy to treat solid tumors.
• ramucirumab (IMC-1121B) · Eli Lilly and Company · Oncology
  Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
• Endostar continuous intravenous infusion · Jiangsu Simcere Pharmaceutical Co., Ltd. · Oncology
  Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.
• Endostar routine intravenous infusion · Jiangsu Simcere Pharmaceutical Co., Ltd. · Oncology
  Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.
• bevacizumab plus chemotherapy · Liaoning Cancer Hospital & Institute · Oncology
  Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), thereby preventing tumor growth and metastasis.

Phase 2 pipeline (4)

• Bevacizumab-containing regimen · Hoffmann-La Roche · Oncology
  Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A).
• Bevacizumab maintenance therapy · Sanofi · Oncology
  Inhibits vascular endothelial growth factor A (VEGF-A)
• Cohort C: bevacizumab · PPD Development, LP · Oncology
  Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A).
• Chemotherapy - Bevacizumab · ARCAGY/ GINECO GROUP · Oncology
  Inhibits vascular endothelial growth factor A (VEGF-A)